Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:25 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
RAD001 Plus Docetaxel in Patients With Metastatic Breast Cancer
NCT00253318 · M.D. Anderson Cancer Center · PHASE1 · terminated · last registry update 2026-06-18 · Breast cancer · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Toxicity and Lack of Efficacy” | – | Registry record, M.D. Anderson Cancer Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against FKBP1A in breast cancer within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-11-05Results posted on the registry: M.D. Anderson Cancer Center, Bevacizumab + Cetuximab (NCT01552434)
- 2026-11-05Also stopped (terminated): M.D. Anderson Cancer Center, Bevacizumab + Cetuximab (NCT01552434)
- 2026-08-12Phase 3 first posted: Fudan University, SHR- A1811+ eve + SHR- A1811 (NCT07760844)
- 2025-07-14Phase 3 first posted: Pfizer, PF-07248144 + Fulvestrant (NCT07062965)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision